Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Hepatic Arterial Infusion
01
Overview
Toripalimab-Sun Yat-sen University-hepatocellular carcinoma refers to a specific combination therapy regimen investigated by Sun Yat-sen University Cancer Center for the treatment of advanced hepatocellular carcinoma (HCC). The regimen integrates systemic immunotherapy with toripalimab (a humanized IgG4 monoclonal antibody targeting PD-1), systemic targeted therapy with lenvatinib (a multi-kinase inhibitor), and localized hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX protocol (oxaliplatin, leucovorin, and 5-fluorouracil). This approach is designed to overcome the limitations of monotherapy in advanced HCC, particularly in patients with high-risk features like portal vein tumor thrombosis (PVTT). Clinical trials, including Phase 2 and Phase 3 studies, have demonstrated that this triple combination significantly improves progression-free survival (PFS) and overall survival (OS) compared to standard-of-care treatments by combining immune activation, anti-angiogenesis, and direct cytotoxic tumor debulking.
- Brand names
- TuoyiLenvima
- Other names
- toripalimab-Sun Yat-sen University-hepatocellular carcinomaToripalimab + Lenvatinib + HAICToripalimab + Lenvatinib + FOLFOX-HAIC
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil.